Literature DB >> 29516627

A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up.

Alexandra Schifferli1, Andreas Holbro2, Meera Chitlur3, Michael Coslovsky4, Paul Imbach5, Hugo Donato6, Mohsen Elalfy7, Elena Graciela8, John Grainger9, Susanne Holzhauer10, Cecilia Riccheri11, Francesco Rodeghiero12, Marco Ruggeri13, Hannah Tamary14, Tatjana Uglova15, Runhui Wu16, Thomas Kühne1,5.   

Abstract

Comparative clinical studies of children and adults with immune thrombocytopenia (ITP) are poorly covered in the literature. However, the accepted classification of ITP-childhood ITP and adult ITP-results in considerable differences in treatment protocols and practice guidelines. The analysis of the Pediatric and Adult Registry on Chronic ITP (PARC-ITP) of patients at first presentation demonstrated fewer differences in clinical and laboratory findings at initial diagnosis between children and adults than expected. The present report of 2-year follow-up data supports the hypothesis that there are common aspects of childhood and adult ITP. Data of 3360 children and 420 adults were collected during the time of 2004 until 2015 at initial diagnosis. Follow-up information was available for 51% and 33% of children and 66% and 49% of adults at 12- and 24-months, respectively. Similarities were found in unexpected areas of ITP, such as the rate of late remission at 12 and 24 months, reported bleeding sites, platelet count in bleeders, and the frequency of treated patients with persistent or chronic ITP. Differences were confirmed for the overall rate of remission and treatment modalities. Unexpected differences were found in the percentage of nonbleeders, with more adults in the nonbleeder group. More studies are needed to investigate different age groups with the aim to optimize their management.
© 2018 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2018        PMID: 29516627     DOI: 10.1002/ajh.25086

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

Review 1.  Pediatric ITP: is it different from adult ITP?

Authors:  Jenny M Despotovic; Amanda B Grimes
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Authors:  Rachael F Grace; Kristin A Shimano; Rukhmi Bhat; Cindy Neunert; James B Bussel; Robert J Klaassen; Michele P Lambert; Jennifer A Rothman; Vicky R Breakey; Kerry Hege; Carolyn M Bennett; Melissa J Rose; Kristina M Haley; George R Buchanan; Amy Geddis; Adonis Lorenzana; Michael Jeng; Yves D Pastore; Shelley E Crary; Michelle Neier; Ellis J Neufeld; Nolan Neu; Peter W Forbes; Jenny M Despotovic
Journal:  Am J Hematol       Date:  2019-04-29       Impact factor: 10.047

3.  Response to rituximab in children and adults with immune thrombocytopenia (ITP).

Authors:  Emily M Harris; Kirsty Hillier; Hanny Al-Samkari; Laura Berbert; Rachael F Grace
Journal:  Res Pract Thromb Haemost       Date:  2021-08-24

4.  Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality.

Authors:  David R Hallan; Christopher Simion; Bao Y Sciscent; John Lee; Elias Rizk
Journal:  Cureus       Date:  2022-04-24

5.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

6.  Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Authors:  Michael D Tarantino; James B Bussel; Victor S Blanchette; Donald Beam; John Roy; Jenny Despotovic; Ashok Raj; Nancy Carpenter; Bhakti Mehta; Melissa Eisen
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

7.  Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients.

Authors:  Marco Dionisi; Sara Cairoli; Raffaele Simeoli; Francesca De Gennaro; Valeria Paganelli; Roberto Carta; Francesca Rossi; Carlo Dionisi-Vici; Giuseppe Palumbo; Bianca Maria Goffredo
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

Review 8.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

9.  Association of Immune Thrombocytopenia and Celiac Disease in Children: A Retrospective Case Control Study

Authors:  Angela Guarina; Maddalena Marinoni; Giuseppe Lassandro; Paola Saracco; Silverio Perrotta; Elena Facchini; Lucia Dora Notarangelo; Giovanna Russo; Paola Giordano; Francesca Romano; Elisa Bertoni; Chiara Gorio; Gianluca Boscarol; Milena Motta; Marco Spinelli; Angelica Barone; Marco Zecca; Francesca Compagno; Saverio Ladogana; Angela Maggio; Maurizio Miano; Gianluca Dell'Orso; Elena Chiocca; Ilaria Fotzi; Angela Petrone; Assunta Tornesello; Irene D'Alba; Silvia Salvatore; Maddalena Casale; Giuseppe Puccio; Ugo Ramenghi; Piero Farruggia
Journal:  Turk J Haematol       Date:  2021-05-18       Impact factor: 1.831

10.  Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia.

Authors:  Panpan Han; Yu Hou; Yajing Zhao; Yang Liu; Tianshu Yu; Yunqi Sun; Haoyi Wang; Pengcheng Xu; Guosheng Li; Tao Sun; Xiang Hu; Xinguang Liu; Lizhen Li; Jun Peng; Hai Zhou; Ming Hou
Journal:  Blood       Date:  2021-08-26       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.